The Supreme Court on Thursday took serious note of a plea to bring transparency in drug pricing and monitoring mechanism while pointing to a recent accusation against the manufacturer of Dolo-650 tablet of indulging in “unethical practices”.
An NGO that has filed the petition said the Central Board of Direct Taxes (CBDT) had accused the pharma group manufacturing the well-known drug of distributing freebies to the tune of ₹1,000 crore to doctors and medical professionals in order to promote its product.
"The 650 mg dosage is irrational," senior advocate Sanjay Parikh, representing the Federation of Medical & Sales Representatives Association of India, submitted.
